Compare AbCellera Biologics Inc (ABCL) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Select Medical Holdings Corporation — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: AbCellera Biologics Inc and Select Medical Holdings Corporation are close in size by market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SEM | |
|---|---|---|
Market Cap | $2.35B | $2.05B |
Sector | Health | Health |
52-Week High | $8.12 | $16.66 |
52-Week Low | $2.78 | $11.77 |
Enterprise Value | $1.99B | $5.01B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Select Medical Holdings Corporation (SEM) trades at $16.51, unchanged on the day, with a bullish technical signal supported by oversold RSI readings. The company reported 2025 revenue of $5.45 billion and net income of $146.22 million, with a P/E ratio of 15.43 and P/S of 0.36 indicating reasonable valuation. Recent news highlights the completion of its acquisition by a consortium led by Robert A. Ortenzio and Martin F. at $16.50 per share, finalized on June 30, 2026.
The acquisition at $16.50 per share, just below the current price, limits near-term upside, while ongoing legal investigations into the board's fiduciary duties pose governance risks. Analyst consensus is mixed with 35.71% buy ratings, but stagnant revenue and declining net income margins signal fundamental challenges. Investors should weigh the acquisition's finality against operational headwinds and shareholder litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
